An 8-year-old girl is referred to the psychiatry clinic by her school for evaluation of persistent inattention and poor academic performance. She is described as a "daydreamer" who frequently loses focus during lessons and forgets instructions. At home, she is quiet and compliant but struggles to complete homework without constant reminders. Her mother denies any hyperactivity or impulsivity. Developmental history is unremarkable. On assessment, she demonstrates intact attention during one-on-one conversation but shows poor sustained attention on continuous performance testing. Which subtype of ADHD is most likely, and what is a key consideration before initiating pharmacotherapy?

Explanation

## ADHD Subtypes and Pre-Treatment Evaluation ### Diagnostic Classification | ADHD Subtype | Inattention Symptoms | Hyperactivity-Impulsivity Symptoms | Prevalence | Clinical Features | |---|---|---|---|---| | **Predominantly Inattentive** | ≥6 symptoms present | <6 symptoms present | ~40% of ADHD cases | "Daydreamers," quiet, forgetful, poor organization, often missed diagnosis | | **Predominantly Hyperactive-Impulsive** | <6 symptoms present | ≥6 symptoms present | ~15% of ADHD cases | Fidgety, talkative, interrupt, act without thinking | | **Combined Type** | ≥6 symptoms present | ≥6 symptoms present | ~45% of ADHD cases | Mixed presentation, most severe, most common | ### Clinical Presentation in This Case **Key Point:** This child presents with **Predominantly Inattentive Type ADHD** because: - Inattention is the primary complaint (daydreaming, forgetfulness, difficulty sustaining attention, loses focus during lessons). - **No hyperactivity or impulsivity** is reported by mother or school. - Quiet and compliant behavior rules out hyperactive-impulsive features. - Poor performance on continuous performance testing confirms sustained attention deficit. **Clinical Pearl:** Inattentive-type ADHD is often underdiagnosed, particularly in girls, because the absence of disruptive behavior makes it less noticeable in classroom settings. These children are often labeled as "lazy" or "unmotivated" rather than recognized as having a neurodevelopmental disorder. ### Pre-Pharmacotherapy Cardiovascular Assessment **High-Yield:** Before initiating stimulant medication, baseline cardiovascular evaluation is **essential** because stimulants increase heart rate and blood pressure and carry a small risk of sudden cardiac death in children with underlying cardiac abnormalities. #### Recommended Pre-Treatment Workup: 1. **Detailed personal and family history** of: - Syncope, palpitations, chest pain, or dyspnea on exertion. - Sudden cardiac death, cardiomyopathy, long QT syndrome, Brugada syndrome, or arrhythmias in first- or second-degree relatives. - Hypertension or hyperlipidemia. 2. **Physical examination:** - Resting heart rate and blood pressure (compare to age-appropriate norms). - Cardiac auscultation for murmurs, arrhythmias, or signs of heart failure. - Assessment for signs of hypertension or tachycardia. 3. **ECG:** Indicated if: - Positive personal or family history of cardiac disease. - Abnormal vital signs. - Abnormal cardiac examination. - Age >40 years (not applicable here, but important in adults). **Warning:** Stimulants are contraindicated in: - Uncontrolled hypertension. - Cardiac arrhythmias (especially long QT syndrome). - Recent myocardial infarction or unstable angina. - Severe structural cardiac abnormalities (e.g., hypertrophic cardiomyopathy). ### Monitoring During Treatment - Reassess BP and HR at each visit (baseline, 2 weeks, 4 weeks, then every 3 months). - Educate parents and child on warning signs: chest pain, syncope, palpitations, severe headache, or unusual fatigue. - Consider non-stimulant alternatives (atomoxetine, guanfacine, clonidine) if cardiac risk is present. **Mnemonic:** **CARD** — **C**ardiovascular history, **A**uscultation, **R**esting vitals, **D**rug contraindications (assess before prescribing stimulants).